Sue E. Craig

Proteomic Analysis of Integrin-Associated Complexes Identifies RCC2 as a Dual Regulator of Rac1 and Arf6

Regulator of chromosome condensation–2 is a component of fibronectin-activated signaling pathways that regulate cell migration. Integrin Interactors Integrins mediate cell-cell adhesion, as well as cell adhesion to the extracellular matrix. Identification of the intracellular signaling networks associated with integrins is of interest because integrins are involved in processes such as invasion of tumor cells during metastasis and leukocyte infiltration during inflammation. Humphries et al. developed a method of isolating protein complexes associated with α5β1 integrin, which binds to fibronectin, and with α4β1 integrin, which binds to vascular cell adhesion molecule–1. Although a subset of proteins was detected in both the α5β1 and α4β1 networks, there were several receptor-specific proteins. In particular, regulator of chromosome condensation–2 (RCC2) was identified as a component of the α5β1 integrin–associated signaling network. RCC2 promoted fibronectin-dependent migration by inhibiting two different subnetworks (Rac1 and Arf6). These techniques provide the means to investigate the composition and function of adhesion complexes under different physiological conditions. The binding of integrin adhesion receptors to their extracellular matrix ligands controls cell morphology, movement, survival, and differentiation in various developmental, homeostatic, and disease processes. Here, we report a methodology to isolate complexes associated with integrin adhesion receptors, which, like other receptor-associated signaling complexes, have been refractory to proteomic analysis. Quantitative, comparative analyses of the proteomes of two receptor-ligand pairs, α4β1–vascular cell adhesion molecule–1 and α5β1–fibronectin, defined both core and receptor-specific components. Regulator of chromosome condensation–2 (RCC2) was detected in the α5β1–fibronectin signaling network at an intersection between the Rac1 and adenosine 5′-diphosphate ribosylation factor 6 (Arf6) subnetworks. RCC2 knockdown enhanced fibronectin-induced activation of both Rac1 and Arf6 and accelerated cell spreading, suggesting that RCC2 limits the signaling required for membrane protrusion and delivery. Dysregulation of Rac1 and Arf6 function by RCC2 knockdown also abolished persistent migration along fibronectin fibers, indicating a functional role for RCC2 in directional cell movement. This proteomics workflow now opens the way to further dissection and systems-level analyses of adhesion signaling.

Anti-integrin monoclonal antibodies

Integrins are a family of 24 heterodimeric transmembrane receptors that support cell-cell and cell-ECM (extracellular matrix) interactions in a multitude of physiological and disease situations ([Humphries, 2000][1]; [Hynes, 2002][2]). Adhesion that is mediated by integrins is controlled dynamically

Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity.

Integrins are a family of heterodimeric adhesion receptors that mediate cellular interactions with a range of matrix components and cell surface proteins. Vascular cell adhesion molecule-1 (VCAM-1) is an endothelial cell ligand for two leukocyte integrins (α4β1 and α4β7). A related CAM, mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is recognized by α4β7 but is a poor ligand for α4β1. Previous studies have revealed that all α4 integrin-ligand interactions are dependent on a key acidic ligand motif centered on the CAM domain 1 C-D loop region. By generating VCAM-1/MAdCAM-1 chimeras and testing recombinant proteins in cell adhesion assays we have found that α4β1 binds to the MAdCAM-1 adhesion motif when present in VCAM-1, but not when the VCAM-1 motif was present in MAdCAM-1, suggesting that this region does not contain all of the information necessary to determine integrin binding specificity. To characterize integrin-CAM specificity further we measured α4β1 and α4β7 binding to a comprehensive set of mutant VCAM-1 constructs containing amino acid substitutions within the predicted integrin adhesion face. These data revealed the presence of key “regulatory residues” adjacent to integrin contact sites and an important difference in the “footprint” of α4β1 and α4β7 that was associated with an accessory binding site located in VCAM-1 Ig domain 2. The analogous region in MAdCAM-1 is markedly different in size and sequence and when mutated abolishes integrin binding activity.

Regulation of integrin activity by MIA.

MIA (melanoma inhibitory activity) has been identified as a small protein secreted from malignant melanoma cells, which interacts with extracellular matrix proteins including fibronectin. Here, we show that MIA negatively regulates the activity of the mitogen-activated protein kinase pathway in malignant melanoma. Using far Western blotting and co-immunoprecipitation we searched for MIA-binding cell surface proteins. We found that MIA interacts with integrin α4β1 and α5β1, leading to down-regulation of integrin activity and reduction of mitogen-activated protein kinase signaling. These findings also suggest that MIA may play a role in tumor progression and the spread of malignant melanomas via mediating detachment of cells from extracellular matrix molecules by modulating integrin activity. Inhibiting MIA functions in vivo may therefore provide a novel therapeutic strategy for metastatic melanoma disease.

Proteomic analysis of α4β1 integrin adhesion complexes reveals α-subunit-dependent protein recruitment

Integrin adhesion receptors mediate cell–cell and cell–extracellular matrix interactions, which control cell morphology and migration, differentiation, and tissue integrity. Integrins recruit multimolecular adhesion complexes to their cytoplasmic domains, which provide structural and mechanosensitive signaling connections between the extracellular and intracellular milieux. The different functions of specific integrin heterodimers, such as α4β1 and α5β1, have been attributed to distinct signal transduction mechanisms that are initiated by selective recruitment of adhesion complex components to integrin cytoplasmic tails. Here, we report the isolation of ligand‐induced adhesion complexes associated with wild‐type α4β1 integrin, an activated α4β1 variant in the absence of the α cytoplasmic domain (X4C0), and a chimeric α4β1 variant with α5 leg and cytoplasmic domains (α4Pα5L), and the cataloguing of their proteomes by MS. Using hierarchical clustering and interaction network analyses, we detail the differential recruitment of proteins and highlight enrichment patterns of proteins to distinct adhesion complexes. We identify previously unreported components of integrin adhesion complexes and observe receptor‐specific enrichment of molecules with previously reported links to cell migration and cell signaling processes. Furthermore, we demonstrate colocalization of MYO18A with active integrin in migrating cells. These datasets provide a resource for future studies of integrin receptor‐specific signaling events.

The “Linker” Region (Amino Acids 38-47) of the Disintegrin Elegantin Is a Novel Inhibitory Domain of Integrin α5β1-Dependent Cell Adhesion on Fibronectin EVIDENCE FOR THE NEGATIVE REGULATION OF FIBRONECTIN SYNERGY SITE BIOLOGICAL ACTIVITY

Disintegrins are a family of potent inhibitors of cell-cell and cell-matrix adhesion. In this study we have identified a region of the disintegrin elegantin, termed the “linker domain” (amino acids 38-47), with inhibitory activity toward α5β1-mediated cell adhesion on fibronectin (Fn). Using a chimeric structure-function approach in which sequences of the functionally distinct disintegrin kistrin were introduced into the elegantin template at targeted sites, a loss of inhibitory function toward α5β1-mediated adhesion on Fn was observed when the elegantin linker domain was substituted. Subsequent analysis comparing the inhibitory efficacies of the panel of elegantin-kistrin chimeras toward CHO α5 cell adhesion on recombinant Fn III6-10 fragments showed that the loss of inhibitory activity associated with the disruption of the elegantin linker domain was dependent upon the presence of a functional Fn III9 synergy site within the Fn III6-10 substrate. This suggested that the elegantin linker domain inhibits primarily the activity of the Fn synergy domain in promoting α5β1 integrin-mediated cell adhesion. Construction of a cyclic peptide corresponding to the entire region of the elegantin linker domain showed that this domain has intrinsic α5β1 inhibitory activity comparable with the activity of the RGDS peptide. These data demonstrate a novel biological function for a disintegrin domain that antagonizes integrin-mediated cell adhesion.

Quantitative proteomic analysis of integrin adhesion complexes

Vascular matrix in health and disease G. Hyde*, A. Marsen and M. Murray *The Cardiovascular Research Group & Wellcome Trust Centre for CellMatrix Research, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK, Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, The University of Manchester, Manchester, UK, School of Biological Sciences, University of East Anglia, Norwich, UK

Development of a proteomic technique to analyze integrin-associated complexes in human embryonic stem cells

Vascular matrix in health and disease G. Hyde*, A. Marsen and M. Murray *The Cardiovascular Research Group & Wellcome Trust Centre for CellMatrix Research, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK, Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, The University of Manchester, Manchester, UK, School of Biological Sciences, University of East Anglia, Norwich, UK